Daniel Sumarriva, Executive Medical Director at SAGA Diagnostics, shared a post on LinkedIn:
“Honored to join the Cure CRC Summit this week along with More than 100 of the leading colorectal cancer researchers, clinicians, patient advocates, and industry partners all together in one room aligned around a single goal: to cure CRC.
The stats show that in the U.S. alone, ~150,000 people will be diagnosed with CRC this year. Too many will relapse and way too many will be identified too late. Therefore we can—and must—do better, faster.
What stood out at this meeting was the shared accountability to recognize that progress will come from true collaboration by linking trials, data, MRD science, and patient centered decision making across silos. The focus on MRD as a critical lever to identify risk earlier, guide intervention, and close gaps where current standards fall short was compelling.
I am grateful to the Colorectal Cancer Alliance for the opportunity to participate, and a special thanks to John Marshall, Scott Kopetz, Emil Lou, and other champions for pushing this field forward with clarity and conviction.
Proud to represent SAGA Diagnostics and to contribute to the collective effort to translate MRD insights into meaningful clinical impact.
This is the equation to accelerate cure:Shared urgency plus accountability plus willingness to challenge the status quo.”
More posts featuring Daniel Sumarriva.
